Patents by Inventor Kathleen Metters

Kathleen Metters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination product and methods of use
    Publication number: 20030130333
    Abstract: A pharmaceutical composition is disclosed which is comprised of an E-type prostaglandin ligand and a COX-2 selective inhibiting compound, in combination with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 26, 2002
    Publication date: July 10, 2003
    Inventors: Chi Chung Chan, Marc Labelle, Kathleen Metters
  • Methods for inhibiting bone resorption
    Patent number: 6586457
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: July 1, 2003
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Shun-Ichi Harada, Mohamed MacHwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
  • Methods of identifying modulators of prostaglandin receptor EP1
    Patent number: 6440680
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: September 13, 1999
    Date of Patent: August 27, 2002
    Assignees: Merck Frosst Canada, Inc., Vanderbuilt University
    Inventors: Anthony Ford-Hutchinson, Colin Funk, Richard Grygorczyk, Kathleen Metters
  • Methods for inhibiting bone resorption
    Patent number: 6414006
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: July 2, 2002
    Assignees: Merck Frosst Canada & Co., Merck & Co., Inc.
    Inventors: Shun-ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc LaBelle, Kathleen Metters, Robert N. Young
  • METHODS FOR INHIBITING BONE RESORPTION
    Publication number: 20020082287
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Application
    Filed: October 13, 1999
    Publication date: June 27, 2002
    Inventors: SHUN-ICHI HARADA, GIDEON A. RODAN, MOHAMED MACHWATE, MARC LABELLE, KATHLEEN METTERS, ROBERT N. YOUNG
  • Methods of identifying modulators of a DP prostaglandin receptor
    Patent number: 6395499
    Abstract: A human prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the human prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Kathleen Metters, Yves Boie, Nicole Sawyer, Deborah M. Slipetz
  • Methods of identifying modulators of human IP prostaglandin receptor
    Patent number: 6365360
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: April 2, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Yves Boie, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
  • Methods of identifying modulators of a prostaglandin receptor
    Patent number: 6358694
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: March 19, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
    Publication number: 20020016342
    Abstract: The present invention provides a method for the treatment or prophylaxis of COX-2-mediated conditions in patients who are at risk of developing thromboembolic events which comprises administering to said patient a therapeutically or prophylactically effective amount of a COX-2 selective inhibitor and a cardiovascular protective amount of a thromboxane inhibitor, as well as compositions therefor.
    Type: Application
    Filed: May 14, 2001
    Publication date: February 7, 2002
    Inventors: Edward Scolnick, Kathleen Metters, Denis Riendeau, Mervyn Turner
  • Methods for stimulating bone formation
    Publication number: 20020004495
    Abstract: The present invention relates to methods for stimulating bone formation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist.
    Type: Application
    Filed: July 3, 2001
    Publication date: January 10, 2002
    Inventors: Shun-Ichi Harada, Gideon A. Rodan, Mohamed Machwate, Marc Labelle, Kathleen Metters, Robert N. Young, Miron Weinreb
  • Methods for inhibiting bone resorption
    Publication number: 20010018433
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Application
    Filed: March 26, 2001
    Publication date: August 30, 2001
    Applicant: Merck & Co., Inc.
    Inventors: Shun-Ichi Harada, Mohamed Machwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
  • COMBINATION PRODUCT AND METHODS OF USE
    Publication number: 20010012845
    Abstract: A pharmaceutical composition is disclosed which is comprised of an E-type prostaglandin ligand and a COX-2 selective inhibiting compound, in combination with a pharmaceutically acceptable carrier. Methods of treatment are also disclosed wherein an E-type prostaglandin ligand and a COX-2 selective inhibiting compound are adminstered in an amount that is effective to treat or prevent an E-type prostaglandin and/or COX-2 mediated disease or condition.
    Type: Application
    Filed: October 22, 1999
    Publication date: August 9, 2001
    Inventors: CHI CHUNG CHAN, MARC LABELLE, KATHLEEN METTERS
  • Methods for inhibiting bone resorption
    Publication number: 20010012838
    Abstract: The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
    Type: Application
    Filed: March 26, 2001
    Publication date: August 9, 2001
    Applicant: Merck & Co., Inc.
    Inventors: Shun-Ichi Harada, Mohamed MacHwate, Gideon A. Rodan, Marc Labelle, Kathleen Metters, Robert N. Young
  • METHODS FOR STIMULATING BONE FORMATION
    Publication number: 20010006980
    Abstract: The present invention relates to methods for stimulating bone formation in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype agonist.
    Type: Application
    Filed: October 13, 1999
    Publication date: July 5, 2001
    Inventors: SHUN-ICHI HARADA, MOHAMED MACHWATE, GIDEON A. RODAN, MARC LABELLE, KATHLEEN METTERS, ROBERT N. YOUNG, MIRON WEINREB
  • DNA encoding prostaglandin receptor DP
    Patent number: 6214972
    Abstract: A novel human DP prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: April 10, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Yves Boie, Kathleen Metters, Nicole Sawyer, Deborah M. Slipetz
  • Purified prostaglandin receptor EP1
    Patent number: 6031079
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: February 29, 2000
    Assignees: Merck Frosst Canada, Inc., Vanderbilt University
    Inventors: Anthony Ford-Hutchinson, Richard Grygorczyk, Collin Funk, Kathleen Metters
  • DNA encoding prostaglandin receptor EP1
    Patent number: 5985597
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: May 26, 1993
    Date of Patent: November 16, 1999
    Assignees: Merck Frosst Canada, Inc., Vanerbilt University
    Inventors: Anthony Ford-Hutchinson, Colin Funk, Richard Grygorczyk, Kathleen Metters
  • DNA encoding prostaglandin receptor DP
    Patent number: 5958723
    Abstract: A novel human DP prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: September 28, 1999
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Yves Boie, Kathleen Metters, Nicole Sawyer, Deborah M. Slipetz
  • DNA encoding prostaglandin receptor FP
    Patent number: 5869281
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: February 9, 1999
    Assignee: Merck Frosst Canada Inc.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • Purified prostaglandin receptor FP
    Patent number: 5840847
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: November 24, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz